Latest stories on KZIA
Kazia gains as Guggenheim is latest to initiate at Buy on lead asset
Seeking Alpha64 · neutralanalyst
Guggenheim initiates Kazia Therapeutics stock with buy rating
Investing.com Analyst Ratings63 · neutralanalyst
Kazia Therapeutics initiated with a Buy at Guggenheim
The Fly63 · neutralanalyst
Why is Kazia Therapeutics stock rallying today?
Investing.com Markets63 · neutralgeneral
Leerink initiates Kazia Therapeutics stock with $30 target
Investing.com Analyst Ratings61 · neutralanalyst
Leerink bullish on Kazia Therapeutics, initiates with an Outperform
The Fly64 · neutralanalyst
Kazia Therapeutics initiated with an Outperform at Leerink
The Fly63 · neutralanalyst
Kazia Therapeutics management to meet with BTIG
The Fly56 · neutralgeneral
Kazia Therapeutics Gains $2 Million Milestone as Sovargen Doses First Paxalisib Patient in Rare Epilepsy Trial
TipRanks63 · neutralproduct/pr
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
PR Newswire63 · neutralproduct/pr
Kazia Therapeutics announces first patient dosed in PNOC035 study
The Fly56 · neutralproduct/pr
BTIG raises Kazia Therapeutics stock price target on trial data
Investing.com Analyst Ratings63 · neutralanalyst
Kazia Therapeutics price target raised to $40 from $34 at BTIG
The Fly63 · neutralanalyst
Kazia Therapeutics announces new preclinical, translational data on paxalisib
The Fly59 · neutralproduct/pr
Kazia Therapeutics expands paxalisib trial into HR+/HER2- breast cancer
The Fly63 · neutralproduct/pr
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
PR Newswire28 · bearishgeneral
Kazia Therapeutics: Worth Speculating On Paxalisib's TNBC Data
Seeking Alpha63 · neutralproduct/pr
Kazia Therapeutics Unveils New Investor-Focused Website
TipRanks55 · neutralgeneral
Kazia Therapeutics stock falls on $40M public offering
Investing.com Markets28 · bearishgeneral